Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26829307 | 0.90 | LMNA (0.53) | ALDH1A1KDM4ELMNATSHRPOLB | |
| SCHEMBL14409534 | 0.90 | LMNA (0.72) | ALDH1A1KDM4ELMNATSHRPOLB | |
| SCHEMBL7484882 | 0.89 | ALDH1A1 (0.57) | ALDH1A1KDM4ELMNATSHRPOLB | |
| SCHEMBL28137499 | 0.89 | POLB (0.70) | ALDH1A1KDM4ELMNATSHRPOLB | |
| SCHEMBL14409536 | 0.86 | SLC6A9 (0.54) | ALDH1A1KDM4ELMNATSHRPOLB | |
| SCHEMBL3735283 | 0.84 | CYP1A2 (0.63) | ALDH1A1KDM4ETSHRPOLBKMT2A | |
| SCHEMBL4187804 | 0.83 | MTNR1A (0.47) | ALDH1A1KDM4ELMNATSHRPOLB | |
| SCHEMBL30123702 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4ELMNAPOLBKMT2A | |
| SCHEMBL24575947 | 0.81 | HPGDS (0.57) | ALDH1A1LMNATSHRKMT2AMEN1 | |
| SCHEMBL11336993 | 0.81 | HPGDS (0.57) | ALDH1A1LMNATSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403842-B1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-06-29 | — | — | EP | claimed |
| EP-2403842-A1 | CHIRAL DISULFONIMIDES | Studiengesellschaft Kohle MbH (DE) | 2012-01-11 | — | — | EP | claimed |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010099786-A1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2010-09-10 | — | — | WO | claimed |
| US-12534484-B2 | Process for preparing dimeric phosphazene derived BrØnsted acids | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2026-01-27 | — | — | US | disclosed |
| EP-4200308-B1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-09-10 | — | — | EP | disclosed |
| CN-120202229-A | Curable polymer compound and resin composition containing the same | 日本化药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-117659092-A | Chiral iminophosphoramidates and derivatives thereof | 科勒研究有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230406870-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-12-21 | — | — | US | disclosed |
| EP-4200308-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | Studiengesellschaft Kohle gGmbH (DE) | 2023-06-28 | — | — | EP | disclosed |
| US-20230108479-A1 | Substituted N-Benzhydrylacetamide Inhibitors of Jamanji Domain Histone Demethylases for the Treatment of Cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-04-06 | — | — | US | disclosed |
| WO-2022073803-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-04-14 | — | — | WO | disclosed |
| US-20070244084-A1 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE | AVENTIS PHARMA SA (FR) | 2007-10-18 | — | — | US | disclosed |
| CN-100336794-C | N-arylation process with hydrazone as ligand in aqueous phase system | UNIV SUN YAT SEN (CN) | 2007-09-12 | — | — | CN | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| CN-1803760-A | N-arylation process with hydrazone as ligand in aqueous phase system | UNIV SUN YAT SEN (CN) | 2006-07-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | ALDH1A1 2503/4885KDM4E 1463/4885LMNA 1127/4885 |
| US-20230108479-A1 | Substituted N-Benzhydrylacetamide Inhibitors of Jamanji Domain Histone Demethylases for the Treatment of Cancer | KDM1B, KDM2A, KDM1A | ALDH1A1 1458/4885KDM4E 31/4885LMNA 2293/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885KDM4E 2725/4885LMNA 4323/4885 |
| US-20230406870-A1 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | PHOSPHO1, BRPF1, BRD9 | ALDH1A1 3679/4885KDM4E 3341/4885LMNA 2296/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | ALDH1A1 351/4885KDM4E 1949/4885LMNA 4828/4885 |
| US-20070244084-A1 | METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE | NPEPPS, DHPS, NISCH | ALDH1A1 1043/4885KDM4E 493/4885LMNA 282/4885 |
| US-12534484-B2 | Process for preparing dimeric phosphazene derived BrØnsted acids | HAT1, LBR, CD79B | ALDH1A1 4176/4885KDM4E 2895/4885LMNA 1775/4885 |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STS, SUDS3, SF1 | ALDH1A1 86/4885KDM4E 2415/4885LMNA 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.